Remote Ischaemic Preconditioning in Transplantation (RIPTRANS)
Recruiting now · Not applicable · Has a placebo group
Conditions studied: Transplant Dysfunction
In brief
Remote ischemic preconditioning (RIPC) is a concept where remotely induced ischemia produces protection against ischemia-reperfusion injury in a remote organ. RIPC has been studied extensively in animal models and heart surgery, but it's benefit in transplantation has been studied less. The primary aim of this study is to find out whether RIPC performed in a donor in donation after brain-death (DBD) could improve delayed graft function rate of kidney transplants.
Key facts
- Study ID
- NCT03855722
- Run by
- Helsinki University Central Hospital
- People needed
- 496
- Starts
- 2019-03-12
- Expected to finish
- 2042-02-01
- Last updated by the study team
- 2020-03-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Helsinki University Hospital — Helsinki, Finland (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.